What Is GLP-1?

Summary: GLP-1 is a hormone your gut releases after meals to tell the pancreas to make insulin and the brain to stop being hungry, and modern weight-loss drugs are long-acting copies of it.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

GLP-1 (glucagon-like peptide-1) is a gut hormone the body produces after eating. It signals the pancreas to release insulin and the brain to slow appetite. Modern GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, are engineered versions of this hormone that last days in the body instead of minutes. That is the short answer. The rest of this page is the biology behind it, the drug class that came out of it, and the 20-year arc from the first injectable to the triple-agonist trials happening right now.

What GLP-1 means and where it comes from

The full name is glucagon-like peptide-1. It is a 30 to 31 amino acid peptide cut out of a larger precursor protein called proglucagon. Specialized cells in the lining of the small intestine and colon, called L-cells, store proglucagon and release GLP-1 into the bloodstream within minutes of food entering the gut ^[1]. Smaller amounts come from neurons in the brainstem, but the gut is the dominant source.

GLP-1 is what physiologists call an incretin. Incretins are hormones the gut releases in response to nutrients that then amplify the insulin response from the pancreas. The other major human incretin is GIP (glucose-dependent insulinotropic polypeptide). Together, GLP-1 and GIP explain why an oral glucose load triggers more insulin release than the same glucose given intravenously. That difference is called the incretin effect, and in type 2 diabetes it is blunted, which is part of why postmeal blood sugar runs high.

So when somebody asks what does GLP-1 mean, the hormone, the literal answer is: a 30-amino-acid peptide secreted by gut L-cells after meals that tells the rest of the metabolic system food has arrived.

What native GLP-1 does in your body

Once GLP-1 is in circulation it binds the GLP-1 receptor (GLP-1R), a G protein-coupled receptor expressed on pancreatic beta cells, alpha cells, stomach lining, kidney, heart, and several brain regions including the hypothalamus and brainstem. Receptor binding triggers four main effects ^[1][2]:

• Insulin release from beta cells, but only when blood glucose is elevated. This glucose-dependent action is why GLP-1 itself rarely causes hypoglycemia.
• Glucagon suppression from pancreatic alpha cells, which reduces how much sugar the liver pours back into the blood between meals.
• Slowed gastric emptying. Food leaves the stomach more gradually, which flattens the post-meal glucose curve and prolongs fullness.
• Appetite suppression. GLP-1 receptors in the hypothalamus and area postrema reduce hunger signaling and increase satiety.

There is also a slower set of effects on beta cell preservation, blood pressure, and cardiovascular tissue that show up in long-term studies but are harder to feel from a single meal.

Why native GLP-1 is useless as a drug

Native GLP-1 has a half-life in the bloodstream of about 1 to 2 minutes ^[1]. An enzyme called dipeptidyl peptidase-4 (DPP-4) chops off the first two amino acids at the N-terminus and inactivates the hormone almost as fast as the gut secretes it. The kidney clears whatever DPP-4 misses. Inject pure native GLP-1 into a patient and most of it is gone before it reaches the pancreas.

That is the engineering problem the entire GLP-1 drug class exists to solve. To turn GLP-1 into a usable medicine you have to make it survive DPP-4 and slow down kidney clearance. The two main tricks are:

1. Change the amino acid that DPP-4 cuts. Swap the second residue (alanine in native GLP-1) for an amino acid the enzyme cannot grip, and DPP-4 stops degrading the peptide.
2. Bind the peptide to albumin. Albumin is the most abundant protein in blood. Attach a fatty acid side chain to the peptide and it sticks to albumin reversibly, which both shields it from kidney filtration and creates a slow-release reservoir.

Combine the two and you get a peptide that hangs around in circulation for days instead of minutes. Semaglutide, the active ingredient in Ozempic and Wegovy, uses both tricks and ends up with a half-life around 7 days ^[3]. Tirzepatide (Mounjaro, Zepbound) uses a similar lipid-attachment strategy on a dual GLP-1/GIP backbone and also lasts about a week ^[4].

The GLP-1 receptor agonist class

The proper name for these drugs is GLP-1 receptor agonists (GLP-1RAs or sometimes GLP-1 analogs). An agonist is any molecule that binds a receptor and triggers the same signal the natural hormone does. GLP-1RAs are not insulin, they are not stimulants, and they are not appetite suppressants in the older amphetamine sense. They are synthetic peptides that activate the body's own GLP-1 receptors and produce the same downstream effects native GLP-1 would, just for much longer.

Most are subcutaneous injections delivered with a pen or a pre-filled syringe. Two are pills: oral semaglutide (Rybelsus) uses an absorption enhancer to get the peptide through the stomach wall, and orforglipron is a small-molecule GLP-1 agonist that does not need any absorption trick because it was never a peptide to begin with.

Why GLP-1 drugs cause weight loss

Native GLP-1 reduces appetite at high physiologic doses. Drug-level GLP-1 receptor activation does this much more aggressively and sustains it for the full week between injections. The mechanism has two parts that act together ^[2]:

The central part is direct receptor binding in hunger-regulating brain regions. The hypothalamus reduces output of orexigenic (hunger-promoting) neurons and increases satiety signaling. The area postrema and nucleus of the solitary tract in the brainstem add a stop-eating reflex similar to what you feel after a large meal. People on therapeutic doses commonly describe food noise quieting, smaller portions feeling satisfying, and a general lack of interest in eating between meals.

The peripheral part is slowed gastric emptying. Food sits in the stomach longer, so the physical sensation of fullness lasts longer and the urge to snack between meals drops.

In the SURMOUNT-1 trial of tirzepatide for obesity, participants on the 15 mg weekly dose lost an average of about 20.9 percent of body weight over 72 weeks ^[4]. The STEP 1 trial of semaglutide 2.4 mg weekly produced about 14.9 percent average loss over 68 weeks ^[3]. For context, that is roughly two to three times what older weight-loss drugs achieved and approaches the magnitude of bariatric surgery results, though surgery still produces deeper and more durable loss in the highest weight categories.

Why GLP-1 drugs help diabetes

Type 2 diabetes is a combined failure of insulin secretion and insulin sensitivity. GLP-1 receptor agonists hit both:

• Glucose-dependent insulin secretion restores some of the meal-response defect. When blood sugar rises, beta cells release more insulin. When blood sugar is normal, they do not, which is why GLP-1RAs as monotherapy carry low hypoglycemia risk.
• Glucagon suppression lowers the liver's contribution to fasting and post-meal hyperglycemia.
• Slowed gastric emptying flattens the postmeal glucose spike.
• Weight loss improves insulin sensitivity over months.

In randomized trials, GLP-1RAs reduce A1C (a three-month average blood sugar) by roughly 0.8 to 1.8 percentage points depending on the agent and dose. Tirzepatide at higher doses produces the largest A1C drops of any non-insulin diabetes drug ever tested. Several agents, including semaglutide and liraglutide, also reduce the risk of major cardiovascular events in people with type 2 diabetes and established cardiovascular disease, which is why cardiology guidelines now treat them as a first-line option for that population alongside SGLT2 inhibitors.

A short history of GLP-1 medications

The story starts in 1980s endocrinology labs, but the clinically interesting timeline begins with the first FDA approval.

2005: Exenatide (Byetta). The first GLP-1 receptor agonist on the US market. Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster, a desert lizard. Exendin-4 happens to be a natural GLP-1 receptor agonist that resists DPP-4. The trade-off was a short half-life that required twice-daily injection.

2010: Liraglutide (Victoza). A semi-synthetic GLP-1 analog with a fatty acid chain that binds albumin, extending the half-life to roughly 13 hours and enabling once-daily dosing. Liraglutide became the first GLP-1 drug approved for weight loss specifically in 2014 under the brand name Saxenda at a higher dose.

2014: Dulaglutide (Trulicity). A GLP-1 fused to a fragment of an antibody, which slowed clearance enough to permit once-weekly injection. The first practical weekly GLP-1 drug.

2017: Semaglutide (Ozempic). A second-generation analog with both an amino acid swap and an upgraded fatty acid linker. Half-life around 7 days. Ozempic was approved for type 2 diabetes in 2017 and the higher-dose obesity formulation, Wegovy, followed in 2021 ^[3]. Oral semaglutide (Rybelsus) launched in 2019.

2022: Tirzepatide (Mounjaro). The first dual agonist to reach the market. Tirzepatide activates both the GLP-1 receptor and the GIP receptor, the two main incretin receptors, with a single weekly peptide. Approved for type 2 diabetes in 2022 and for weight management as Zepbound in late 2023 ^[4]. In head-to-head and cross-trial comparisons it produces the largest weight loss of any approved drug.

2023 to 2026: Triple agonists in trials. Retatrutide, Eli Lilly's investigational follow-up to tirzepatide, activates GLP-1, GIP, and the glucagon receptor simultaneously. In phase 2 trials it produced average weight loss above 24 percent at the highest dose over 48 weeks ^[5]. Phase 3 data is the next major readout. Orforglipron, the first oral small-molecule GLP-1 agonist, received its first FDA approval for chronic weight management in 2026.

The arc is consistent: each generation extends dosing intervals, adds receptors, or removes the injection requirement. Side effect profiles have shifted only modestly. Nausea, vomiting, and constipation remain the dominant adverse events across all agents.

The broader endocrine context

GLP-1 is one piece of a coordinated post-meal signaling system. After you eat, the gut releases at least three relevant peptides almost simultaneously:

• GLP-1 from L-cells (insulin up, appetite down, gastric emptying slowed).
• GIP from K-cells in the upper small intestine (insulin up, lipid handling changes).
• PYY (peptide YY) from L-cells (appetite down, gastric emptying slowed).

Older drugs targeted only GLP-1. Tirzepatide added GIP. Retatrutide adds glucagon, which sounds backward (glucagon raises blood sugar) but at chronic low-level receptor activation it increases energy expenditure and lipolysis. Future agents will likely add PYY, amylin, or other gut peptides as research clarifies which combinations produce the best balance of weight loss, glycemic control, and side effect tolerance. The class name "GLP-1 medications" is already a slight oversimplification, since tirzepatide is not purely a GLP-1 drug. The accurate umbrella term is incretin-based therapy or gut hormone-based therapy, but in everyday language GLP-1 is what stuck.

Common myths worth correcting

People hear contradictory things about GLP-1 from social media, weight-loss clinics, and their friends. A short list of the most common misunderstandings:

"It's just water weight." No. Body composition studies using DEXA scans show that the majority of weight loss on GLP-1 drugs is fat mass, with some lean tissue loss that resistance training and protein intake mitigate.

"It melts fat directly." No. GLP-1 drugs do not have a direct lipolytic effect at therapeutic doses. They reduce calorie intake, and the resulting energy deficit forces the body to burn stored fat. The mechanism is appetite, not metabolism magic.

"You have to be on it forever or you regain everything." Mostly true, and the same is true of every chronic disease treatment. Obesity and type 2 diabetes are chronic conditions. Stop the drug and the underlying physiology that produced excess weight or high blood sugar reasserts itself. People who pair the drug with sustained habit change retain more of the loss after stopping than people who do not, but average regain is real.

"It causes thyroid cancer." GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors based on findings in rats, where the species responds differently than humans. Large human studies have not confirmed a clinically meaningful thyroid cancer signal, but the warning remains and people with a personal or family history of medullary thyroid carcinoma or MEN-2 should not take these drugs.

"It is the same as a stimulant." No. Stimulants like phentermine raise heart rate and blood pressure and act on noradrenaline pathways. GLP-1 drugs do neither of those things at therapeutic doses. They reduce appetite by activating a gut hormone receptor system, which is mechanistically unrelated.

Common questions about GLP-1

Does your body naturally produce GLP-1?

Yes. L-cells in the small intestine and colon release GLP-1 within minutes of eating, and smaller amounts come from brainstem neurons. Native GLP-1 has a half-life of only 1 to 2 minutes because DPP-4 inactivates it quickly.

Where is GLP-1 produced in the body?

Mostly in L-cells lining the lower small intestine and colon. The brainstem also produces small amounts. Both sources release it in response to nutrients reaching the gut.

What does GLP-1 do to your body?

It stimulates glucose-dependent insulin release from the pancreas, suppresses glucagon, slows gastric emptying, and reduces appetite via receptors in the hypothalamus and brainstem.

What does GLP-1 stand for?

Glucagon-like peptide-1. It is a 30-amino-acid peptide cut from the proglucagon precursor protein, named because part of its sequence resembles the glucagon hormone.

Is GLP-1 a digestive enzyme?

No. GLP-1 is a hormone, not an enzyme. It does not break down food. It signals the pancreas, brain, and stomach to coordinate the body's response to a meal.

How is GLP-1 different from insulin?

Insulin is produced by pancreatic beta cells and directly lowers blood sugar by moving glucose into cells. GLP-1 is produced by gut cells and triggers insulin release, suppresses glucagon, and reduces appetite. GLP-1 acts upstream of insulin.

Are Ozempic and Wegovy the same drug?

Yes, both contain semaglutide. Ozempic is the diabetes formulation, Wegovy is the higher-dose obesity formulation. The molecule is identical.

Is tirzepatide a GLP-1 drug?

Tirzepatide activates the GLP-1 receptor and the GIP receptor. It is technically a dual incretin agonist, but the class is commonly grouped under the GLP-1 medications umbrella.

What was the first GLP-1 drug?

Exenatide (Byetta), approved by the FDA in 2005. It is a synthetic version of exendin-4, a peptide from Gila monster venom that happens to be a natural GLP-1 receptor agonist resistant to DPP-4.

What is the newest GLP-1 drug?

Retatrutide, a triple agonist hitting GLP-1, GIP, and glucagon receptors, is in late-stage trials and produced the deepest weight loss yet recorded for an injectable obesity drug. Orforglipron, the first oral small-molecule GLP-1, gained its first approval in 2026.

Can GLP-1 drugs cure diabetes?

They control type 2 diabetes effectively, often reducing A1C by more than a percentage point, but they do not cure it. Stopping the drug returns blood sugar toward pretreatment values. Type 1 diabetes is not treated with GLP-1 drugs because it is an autoimmune insulin-deficiency disease, not a regulation problem.

How long do GLP-1 drugs last in the body?

Native GLP-1 lasts 1 to 2 minutes. Liraglutide lasts about 13 hours. Semaglutide and tirzepatide have half-lives around 5 to 7 days, which is why they are dosed once weekly.